Regulation & Compliance

Access earns its fourth Best in KLAS award for data archiving, a win that underscores deep customer trust and the critical role of smart data management.

The digital health giant now offers a 50+ cancer blood test, promising early detection. But experts caution on its limits and lack of FDA approval.

At HIMSS 2026, Hyland unveils agentic automation tools to slash paperwork, streamline workflows, and give clinicians more time for patient care.

Amid Georgia's economic boom, PEO giant FrankCrum expands, banking on its unique insurance model to win over businesses in a competitive landscape.

A Chinese tech firm plans to bring its automated parking solutions to NYC and LA, facing a crowded market, financial hurdles, and geopolitical scrutiny.

An exclusive FDA invite positions IKE Tech’s blockchain-based age-gating system at the heart of future vape regulation, a move that could redefine the industry.

Huntington Bank partners with Ameriprise, shifting $28B in assets to a new platform in a strategic move shaking up the wealth management landscape.

A new partnership with Restb.ai brings AI-powered image analysis and compliance checks directly into the NAVICA MLS, aiming to save agents time and improve data.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

The Center for the Future of Arizona launches a free, data-driven hub to equip journalists and combat declining public trust in media.

In a landmark deal for Canadian fintech, a federally regulated bank will custody QCAD's reserves, paving the way for institutional stablecoin adoption.

Thousands, including minors, were secretly filmed in Northwell Health bathrooms. A new lawsuit exposes the breach and a year-long notification delay.

A powerful new genomic tool is turning genetic doubt into diagnostic certainty, helping thousands of patients understand their true hereditary cancer risk.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

As Crown Crafts preps its Q3 earnings, investors watch to see if strategic shifts can overcome financial pressures in the competitive juvenile products market.

Markets are calm, but concerns over US Federal Reserve independence add a new layer of risk to global trade, threatening borrowing costs and stability.

As OneMain CEO Doug Shulman prepares for a key conference, all eyes are on the lender's strategy for navigating a complex economic and regulatory landscape.

As the FDA embraces advanced Bayesian statistics, MedTech firm BioStem sees validation for its wound care research, promising faster innovation for patients.